Therefore, blocking IFNγ by CREKA-lipo-anti-IFNγ has the potential to prevent capillary leak syndrome and venous thromboembolism in cancer patients undergoing chemotherapy, which merits further studies. The gene discussed is IFNG; the disease is capillary leak syndrome.